Suppr超能文献

相似文献

1
Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement.
Clin J Am Soc Nephrol. 2011 May;6(5):1009-17. doi: 10.2215/CJN.07110810. Epub 2011 Mar 17.
2
Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy.
Pediatr Nephrol. 2019 Aug;34(8):1311-1323. doi: 10.1007/s00467-018-3989-0. Epub 2018 Jun 9.
5
C4 Nephritic Factors in C3 Glomerulopathy: A Case Series.
Am J Kidney Dis. 2017 Dec;70(6):834-843. doi: 10.1053/j.ajkd.2017.07.004. Epub 2017 Aug 24.
6
Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN.
Front Immunol. 2018 Oct 15;9:2329. doi: 10.3389/fimmu.2018.02329. eCollection 2018.
9
Causes of alternative pathway dysregulation in dense deposit disease.
Clin J Am Soc Nephrol. 2012 Feb;7(2):265-74. doi: 10.2215/CJN.07900811. Epub 2012 Jan 5.
10
C3 Glomerulopathy and Related Disorders in Children: Etiology-Phenotype Correlation and Outcomes.
Clin J Am Soc Nephrol. 2021 Nov;16(11):1639-1651. doi: 10.2215/CJN.00320121. Epub 2021 Sep 22.

引用本文的文献

1
The role of B lymphocyte subsets in nephrotic syndrome: functions, mechanisms, clinical significance and future perspectives.
Front Immunol. 2025 Aug 7;16:1598197. doi: 10.3389/fimmu.2025.1598197. eCollection 2025.
3
Acquired drivers of C3 glomerulopathy.
Clin Kidney J. 2025 Jan 27;18(3):sfaf022. doi: 10.1093/ckj/sfaf022. eCollection 2025 Mar.
5
Eculizumab as a treatment for C3 glomerulopathy: a single-center retrospective study.
BMC Nephrol. 2023 Jan 11;24(1):8. doi: 10.1186/s12882-023-03058-9.
6
Renal injury in scleromyxoedema due to monoclonal gammopathy associated C3 glomerulonephritis.
BMJ Case Rep. 2022 Nov 30;15(11):e250296. doi: 10.1136/bcr-2022-250296.
8
Clinical Presentation, Renal Histopathological Findings, and Outcome in Patients with Monoclonal Gammopathy and Kidney Disease.
Int J Nephrol. 2021 May 12;2021:8859340. doi: 10.1155/2021/8859340. eCollection 2021.
9
C4d at Crossroads Between Post-Infectious Glomerulonephritis and C3 Glomerulopathy.
Int J Nephrol Renovasc Dis. 2021 Mar 11;14:87-95. doi: 10.2147/IJNRD.S285302. eCollection 2021.
10
Deposition of the Membrane Attack Complex in Healthy and Diseased Human Kidneys.
Front Immunol. 2021 Feb 11;11:599974. doi: 10.3389/fimmu.2020.599974. eCollection 2020.

本文引用的文献

1
Dense deposit disease associated with monoclonal gammopathy of undetermined significance.
Am J Kidney Dis. 2010 Nov;56(5):977-82. doi: 10.1053/j.ajkd.2010.06.021. Epub 2010 Sep 15.
2
C3 glomerulopathy: a new classification.
Nat Rev Nephrol. 2010 Aug;6(8):494-9. doi: 10.1038/nrneph.2010.85. Epub 2010 Jul 6.
3
Membranoproliferative glomerulonephritis secondary to monoclonal gammopathy.
Clin J Am Soc Nephrol. 2010 May;5(5):770-82. doi: 10.2215/CJN.06760909. Epub 2010 Feb 25.
5
Complement regulators and inhibitory proteins.
Nat Rev Immunol. 2009 Oct;9(10):729-40. doi: 10.1038/nri2620. Epub 2009 Sep 4.
6
Glomeruli of Dense Deposit Disease contain components of the alternative and terminal complement pathway.
Kidney Int. 2009 May;75(9):952-60. doi: 10.1038/ki.2008.657. Epub 2009 Jan 28.
7
Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients.
Clin J Am Soc Nephrol. 2009 Jan;4(1):22-32. doi: 10.2215/CJN.03480708. Epub 2008 Oct 29.
8
C3 deposition glomerulopathy due to a functional factor H defect.
Kidney Int. 2009 Jun;75(11):1230-1234. doi: 10.1038/ki.2008.354. Epub 2008 Jul 16.
9
Cryoglobulinemia and renal disease.
Curr Opin Nephrol Hypertens. 2008 May;17(3):243-9. doi: 10.1097/MNH.0b013e3282f8afe2.
10
Marfan syndrome, MPGN, and bacterial endocarditis.
Am J Kidney Dis. 2008 Apr;51(4):697-701. doi: 10.1053/j.ajkd.2007.08.031. Epub 2008 Mar 3.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验